Statement of Changes in Beneficial Ownership (4)
May 31 2016 - 5:53PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
FUCHS HENRY J
|
2. Issuer Name
and
Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC
[
BMRN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
EVP, Chief Medical Officer
|
(Last)
(First)
(Middle)
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/26/2016
|
(Street)
SAN RAFAEL, CA 94901
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
5/26/2016
|
5/26/2016
|
M
|
|
15000
|
A
|
$26.49
|
130914
|
D
|
|
Common Stock
|
5/26/2016
|
5/26/2016
|
S
|
|
10000
|
D
|
$88.04
(1)
|
120914
|
D
|
|
Common Stock
|
5/26/2016
|
5/26/2016
|
S
|
|
5000
|
D
|
$87.34
(2)
|
115914
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Common Stock (Right to buy Common Stock)
|
$26.49
|
5/26/2016
|
5/26/2016
|
M
|
|
|
15000
|
11/12/2011
|
5/11/2021
|
Common Stock
|
15000
|
$0
|
65225
(3)
|
D
|
|
Explanation of Responses:
|
(
1)
|
All shares were sold at the same price
|
(
2)
|
The price in column 4 is a weighed average price. The price actually received ranged from $86.50 to $88.34. The reporting person will provide to the issuer, and security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
|
(
3)
|
Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
FUCHS HENRY J
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL, CA 94901
|
|
|
EVP, Chief Medical Officer
|
|
Signatures
|
/s/ Laura Randall Woodhead, Attorney-in-Fact
|
|
5/31/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2024 to May 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From May 2023 to May 2024